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Introduction

Hairy
cells
(HCs),
derived
from
the
peripheral
blood and spleen of hairy cell leukemia
(HCL) patients,
constantly
displayed both
ruffles
and microvilli.
HCs which were kept in culture
for
up to three days exhibited
extremely polarized
and
active
surfaces
with elongated
microvilli
and
exaggera ted "spiked" ruffles.
Cells derived from
11 cases of HCL were treated with alpha-interferon
(IFN) in-vitro
and examined by immuno - scanning
electron
microscopy (immuno-SEM). In 8 cases,
up
to one-third
of the
IFN-treated
hairy
cells
displayed
deformed
surfaces
with
"bubbling"
membrane and markedl y villous bud-like formations.
Monoclonal antibodies
(MoAb), used in conjunction
with
immuno-qold labeling,
facilitated
better
correlation
between these
morphological
changes
and the immunological profiles
of the cells before
and after interferon
treatment
in-vitro.
ImmunoSEM analyses revealed no remarkable changes in the
labeling
of HCs with Leu-14 and Leu-MS MoAbs
before
and after IFN treatment,
even in cases
showing membrane changes.
However, a significant
icrease in the labeling
intensity
for HLA-DR and
HLA-DQ was noticed in HCs from cases
where IFNinduced membrane changes were evident.
A review of
the literature
on membrane changes in IFN-treated
cells
proposes that
such immuno-ultrastructural
alterations
might reflect
unique
interferoninduced
membrane reorganization
in the target
malignant cells.

For the first
twenty years
following
its
discovery
by Isaacs
and
Lindenmann
[1957],
interferon
(IFN) was studied
as an antiviral
agent.
Currently,
the inhibition
of
virus
multiplication
('antiviral
effect'),
the
inhibition
of cell proliferation
('antimitogenic
effect'),
and cell regulatory
activities,
such as
effects
on cell
differentiation
and
immune
functions,
are the most important effects
of IFN.
On the other hand, several groups of proteins
were
found to be induced by IFN, namely,
translationregulatory
enzymes,
cell
surface
antigens
and
intracellular
proteins
detected
by
gel
electrophoresis
[Taylor-Papadimitriou,
1980; Van
Damme and Billiau,
1981; Vilcek
et al.,
1982:
Friedman and Vogel, 1983]. Besides
intracellular
and surface
proteins,
IFN treatment
may also
affect
the activity
of genes for cytoskeletal
proteins
[Tamm et al., 1982; Wang et al.,
1984;
discussed by Revel, 1984] . The resulting
changes
in the cytoskeleton
are numerous and could lead to
abortive mitosis as well as to abnormal control of
cell size, shape, and function.
Human interferons
were successfully
harnessed
in
t he treatment
of various
viral
diseases
[Merigan,
1981].
Effective
therapy
with
IFNs,
derived
from cell culture or cloning
technology,
was also reported in hairy cell
leukemia
(HCL),
chronic
myelocytic leukemia, IgA myelomas,
renal
cancer,
skin
cancers
due to
papillomavirus,
melanomas, and metastatic
breast cancer [Strander,
1983; Bonnem and Spiegel,
1984].
Studies
have
shown that IFN lead to the elimination
of cancer
cells
in the blood or the tissues
of the treated
patients,
but the actual mechanism of its
action
is still
unknown.
HCL is
characterized
by
pancytopenia,
splenomegaly,
and infiltration
of the bone marrow
and spleen by distinct
abnormal mononuclear
cells
[Golomb et al.,
1983].
Since HCL might
be
confused with other malignant lymphomas or chronic
lymphocytic
leukemia,
which are treated
in an
utterly
different
manner, accurate
diagnosis
of
HCL is important.
It is preferable
initially
to
advise
only splenectomy,
or no treatment,
rather
than radiotherapy
or chemotherapy
[Golomb and
Vardiman, 1983].
However, recent clinical
studies
indicated
that
most HCL patients
treated
with
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alpha-IFN
showed a striking
clinical
response
to
the drug [Quesada et al., 1984].
Most
scanning
electron
microscopy
(SEM)
studies
on hairy cells (HCs) initially
aimed to
determine whether these cells were of lymphocytic
or monocytic origin [references
cited in Gamliel
et al.,
1985].
Generally,
these
SEM studies
revealed
cells
displaying
ruffles
(monocytoid
features)
mixed with microvilli
(lymphocytoid
features),
making it
impossible
to favor
a
lymphocytic
or monocytic nature of the HC under
the SEM. However, recent multidisciplinary
studies
have proven that
HCL cells
are malignant
Blymphocytes
which display
some
monocyte-like
characteristics
[Reiber et al., 1977; Burns and
Lawley, 1979; Yanovich et al., 1979;
Golomb et
al., 1982; Jansen et al., 1982].
Based on the surface morphology of HCs from 18
patients,
Gamliel
et al. [1985] identified
two
major types
of hairy cells:
(i)
cells
showing
areas
of ruffles
alongside
areas
of clustered
microvilli,
and (ii) cells displaying
microvilli
scattered
among ruffles.
The clinical
efficacy of alpha-IFN in HCL led
us to utilize
the SEM for the study of the effect
of IFN on HCs in-vitro.
In a previous
paper
[Gamliel et al., 1987], we reported for the first
time that
HCs treated
with alpha-IFN
in-vitro
displayed
unique
alterations
in their
surface
morphology.
The present report extends
on seven
more HCL cases treated with IFN in-vitro,
and
reviews
other
studies on IFN-induced
membranal
alterations.
Materials

were removed from the mononuclear
band of the
gradient,
and washed three
times in HBSS or
Dulbecco's phosphate buffered saline (DPBS). Using
this
procedure, more than 80% of the mononuclear
splenic
cells
were HCs, while the number of
monocytes never exceeded 5% in all PB and spleen
samples. PB cells from 6 HCL patients
and splenic
cells from 5 other cases were treated with IFN in6
vitro.
Cell
suspensions
(10 cells),
in 2.5 ml
RPMI medium 1640 and 10% fetal calf
serum, were
incubated
in tissue culture flasks,
at 37°c in a
5% CXl humidified
atmosphere.
After
24 h of
incubaton,
RDa -IFN (recombinant human leukocyte
2
interferon;
Schering Corp., Bloomfield, NJ)
in a
0.9% NaCl solution was added at a concentration
of
1000
international
units
per 1 ml.
Control
cultures
received NaCl solution without
IFN, or
IFN in the presence of neutralizing
concentration
(50 µl/1000 IU IFN) of rabbit
anti-IFN
reagent
(Interferon
Sciences, Inc., New Brunswick,
NJ).
Cultures were harvested on the first,
second,
and
third
days of incubation
for viability
and
differential
cell counts, and for SEManalyses.
In
some cases, usually those with high blood counts,
cells
were also harvested after 2, 4, and 6 h.
Viable cell
counts were performed
using
trypan
blue dye exclusion.
For routine SEM examinations,
cells
were fixed with 2% glutaraldehyde
in DPBS
for 1 h.
The following monoclonal antibodies
(Becton
Dickinson,
Mountain View, CA) were used to study
control
and treated cells:
Leu-4 (specific
for
T
cells),
Leu-14 (for B cells),
Leu-M3
(for
monocytes/macrophages),
Leu-MS (for hairy
cells
and monocytes),
anti-HLA-DR ( for B---cells
and
monocytes),
and anti-HLA-DQ (Leu-10; for B cells
and monocytes ) .
For immune-gold labeling,
cells were fixed in
0.2% glutaraldehyde
for 10 min, washed with DPBS,
and treated
with 0.lM glycine for 5 min. Cells
were then washed with DPBS, loaded on poly-Llysine
treated
glass
coverslips
for 1 h, and
washed with an 'immune' buffer (DPBS containing
1%
bovine
serum albumin and 1% decomplemented
human
AB serum). Subsequently,
cells were reacted
with
50 µl of diluted monoclonal antibody for 30 min,
washed 3 times with the
'immune' buffer,
and
incubated
with 50 µl of 40 nm colloidal
gold
particles
tagged with goat
anti-mouse
MoAb
(GAMigG+IgM-G40;
Janssen
Pharmaceutica,
Piscataway,
NJ). After 30 min, cells were rinsed
with DPBS and postfixed
in 2% glutaraldehyde
until
processed for SEM.
SEM preparation
of cells
was carried
out
using either conventional
critical
point
drying
(CPD), or the newly introduced GI'GO - air
drying
(GTGO-AD)procedure which minimizes cell shrinkage
due to improved fixation
routine
[Gamliel et al.,
1983; Gamliel, 1985]. Briefly,
after fixation
with
glutaraldehyde,
coverslips
with a monolayer
of
attached
cells were either processed
immediately
for CPD [Gamliel, 1985], or incubated
in DPBS
containing
2% tannic acid and 2% guanidine-HCl,
for 1 h, as part
of the GI'GO-AD procedure.
Thereafter,
cells were thoroughly washed for
15
min with DPBS and subsequently
immersed in DPBS
containing
2% osmium tetroxide
for another
hour.
Dehydration
was carried
out through
a graded
series
of ethanol in distilled
water
(25%, 50%,

and Methods

The main guidelines
for including HCL cases
in this
study were: patients
with the leukemic
form of their
disease,
i.e.,
those who had
greater
than
60% abnormal
cells
in
the
differential
c~unts and greater than 10,000 white
blood cells/mm.
These criteria
were set as it
is
relatively
easy to score the HCs in such cases
in
comparison to most HCL patients
who are leukopenic
with less than 10% HCs. Eleven such patients
were
selected
for evaluation
of cell surface
features
before and after IFN treatment.
HCL was diagnosed
by the following tests:
the presence of
'hairy'
cells
in the peripheral
blood (PB) and/or
bone
marrow and spleen; the existence
of tartrateresistant
acid phosphatase
isoenzyme
in
the
malignant cells;
the demonstration
by transmission
electron
microscopy (TEM) of a ribosome-lamella
complex
in
some
cells;
the
presence
of
splenomegaly
and
pancytopenia,
and
a
chronic
clinical
course.
For the isolation
of PB-HCs, samples of
venous blood were collected
in sterile
evacuated
tubes
(Vacutainer
Systems,
Rutherford,
NJ)
containing
heparin
as an anticoagulant,
and
layered
on a Ficoll-Paque
gradient
(see below).
For the isolation
of spleen HCs, 2.5 centimeter
sections of fresh spleen tissue were kept in cold
Hank's balance::! salt
solution
( HBSS) with 1%
heparin
while
they were gently teased
across
a
sterile
fine
mesh screen,
producing
a liquid
homogenate.
Mononuclear cells were isolated
from
the peripheral
blood and/or the spleen
homogenate
by the Ficoll-Paque
density gradient method. Cells
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Fig. 1a:
clustered
membrane.
Fig. 1b:
cultivation
exaggerated

Control,
microvilli

untreated
beside

HCL cells
prominent

Control
HCL cells
after
without
interferon,
ruffles
and microvilli.

surface

alterations

Fig. 2a:
IFN-treated
spleen
hairy cell
showing a
bud-like
formation
(arrows)
and bubbling
membrane
on the cell body and ruffles
(wide arrows).
Fig. 2b : IFN-treated
peripheral
blood HCL cell
displaying
a villous
bud-like
formation
(arrows)
and areas of bubbling
membrane (wide arrows).

showing
ruffled

one
day
of
displaying

75% and three times 100%) followed by a graded
series of Freon 113 (TF) in absolute ethanol (25%,
50%, 75% and three times 100%), for 10 min in each
solution.
Samples fully immersed in Freon 113 were
picked
out one by one with delicate
forceps
and
vigorously shaken in the air for about 10s. After
drying,
specimens were mounted on
Cambridge
aluminum stubs using double-sided
sticky tape or a
gluey
silver
paint.
Coverslips
with the cell
monolayers were coated with a thin layer of carbon
using
a sputter coater apparatus
(SPI Supplies,
West Chester,
PA). While JEOL JSM-35 SEM was
used in the preliminary
studies,
the JEOL 840A,
equipped
with highly-sensitive
annular
type
backscattered
electron image (BEI) detector,
was
used in recent studies.
Attempts to use the GI'GOAD technique
for preparing
gold-labeled
cells

resulted
in the inability
to get BEI of the gold
particles
because of the high background
signal
contributed
by the heavy metal solution
(Oso4 ).
Results
Control PB-HCs were similar to those isolated
from the spleen,
showing variable
numbers of
microvilli,
and a wide spectrum of ruffles
(Fig.
la)
with minute spikes outlining
their
uppermost
profile
("spiked-ruffles").
cultured HCs exhibited
large
ruffles
as well as clusters
of microvilli,
and consistent
polarity
of these surface
features
(Fig.
lb). Many of these cultured
HCs displayed
exaggerated,
undulating,
broa:i-based,
"spiked"
ruffles,
whereas clusters
of elongated
microvilli
were often encountered.
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The majority of IFN-treated
HCs displayed the
same
surface
features
characterizing
their
cultured,
untreated
equivalents.
However, distinct
surface alterations
were found in about one-third
(19 to 36%) of the HCs from the PB and spleen
specimens
in 8 out of the 11 cases
treated
with
IFN in-vitro.
These changes
comprised
the
appearance
of a "bubbling" membrane on the cell
body and/or on the ruffles
(Figs. 2a,b), while the
microvilli
became much shorter compared to the
microvilli
of the cultured,
untreated
cells.
The
majority
of these cells also showed a bud-like
formation
at their extremity
(Figs.
2a,b)
which
was markedly villous
and frequently
was the only
villous part of the cell. The same type of surface
changes were found in the parallel
samples which
underwent CPD after GA fixation.
None of the above
described surface alterations
were encountered
in
control
specimens
treated
with IFN-free
NaCl
solution,
nor in cultures
that were treated
with
IFN and a neutralizing
concentration
of an antiIFN reagent.
Some of the above described changes were also
found in the cultures
after
2, or 4 h
of
incubation
in the presence of IFN. These cells
primarily
showed bud-like
structures
whereas
'bubbling'
membranes were rarely seen.
However,
these
early changes were found in less
than 1S%
of the HCs.
Correlative
immuno-SEM studies were performed
to determine
the immunological profiles
of the
control
untreated
cells,
and the cultured
cells
with and without IFN treatment.
Highly specific
monoclonal antibodies
were used to label the cells
for B (Leu-14) and T (Leu-4) antigens,
and for
antigens presented by monocytes (Leu--M3, Leu-MS),
and hairy cells (Leu-MS) • In addition,
we used
anti-HLA-DR and anti-HLA-DQ (Leu-10) reagents
to
assess the expression of class II HLA antigens
on
the treated
cells.
These immuno-gold labeling
studies
were done on 7 out of the 11 IFN-treated
cases.
All of these cases were positive
(higher
than 60% labeled cells)
for Leu-14, Leu-MS, HLA-DR
and HLA-DQ, and negative (less than S% labeled
cells)
for Leu-4 and Leu-M3. In 2 of these
cases
neither
morphological
nor
immunophenotypical
changes were noted. The other S cases showed IFNinduced
membrane changes,
rut
displayed
no
significant
alterations
in labeling pattern
with
Leu-14 and Leu-MS (Fig. 3). However, all these
S
cases
showed a significant
increase
in
the
labeling pattern for HLA-DQand HLA-DR (Fig. 4).
Diverse
types
of normal
and
leukemic,
circulating
and cultured leukocytes were used as
controls in this study. Normal mononuclear
cells,
chronic lymphocytic leukemia and myeloid
leukemia
cells,
all
did not show any noticeable
immunoultrastructural
changes when treated with IFN invitro.
On the
other
hand, Daudi (B-lymphoma)
cultured
cells
did display a change in their
villousity.
These alterations,
which were quite
different
from those
exerted
by
HCs,
were
accompanied by an increase in the expression
of
class
II HLA antigens.
The above changes were
abrogated when these cultures
were treated with a
neutralizing
concentration
of anti-IFN.
Trypan blue test and careful SEM examinations
were used to test changes in the viability
rates
of control
vs. IFN-treated
HCs. In all
studied
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cases,
no significant
differences
in the numbers
of viable
cells were noted,
and the viability
rates were always over 7S% of the total number of
the cells.
Discussion
Interferons
are
reported
to
directly
stimulate
cell
killing
by
enhancing
the
cytotoxicity
of T-lymphocytes [Sethi and Brandis,
1978; Zarling
et al.,
1978],
of
macrophages
[Schultz
and Chirigos,
1979; Stanwick
et al.,
1980], of monocytes [Jett et al., 1980], and of NK
cells
[Welsh,
1981; Herberman et al.,
1982]
against viral-infected
cells or tumor cells.
The
mechanism
is unknown but it may be related
to
increased
synthesis
and expression
of membrane
antigens,
or may reflect
differentiation
of the
immune cells under the influence of IFN.
Since alpha-,
beta-,
and gamma-IFN
also
stimulate
HLAclass I antigen synthesis
and the
expression
on the cell
surface
of antigen-HLA
complexes,
it is possible that this enhances
the
ability
of the immune cells to recognize
cells
presenting
non-self
antigens
and destroy
them
[Revel,
1984]. This effect of IFN on recognition
of non-self antigens on target cells has not been
demonstrated
in-vitro.
However,
when
immune
deficient
patients
with low HLA-Aor B expression
are
treated
with IFN, their
cells
show
an
increased
ability
to be recognized
by specific
cytotoxic T cells [Durandy et al . , 1983].
Studies
have suggested that
alpha-,
beta-,
and
garrrna-IFNs first
bind to
cell
surface
receptors
and subsequently
induce an intracellular
response [reviewed by Revel, 1984]. After a rapid
initial
binding of IFN, clustering
and activation
of the IFN receptors
can take place [Shulman and
Revel, 1980], and the interaction
of IFN with cell
membranes seems needed to induce the biological
response.
In a preliminary
study we have shown that
when HCs are treated
in-vitro
with alpha-IFN,
dramatic changes in surface architecture
occur
in
up to 32% of the HCs from 3 out of 4 HCL patients
[Gamliel
et al., 1987].
We have also shown that
the IFN-induced surface alterations
were dose and
time dependent,
however, the most dramatic changes
were encountered in cells treated with 1000 IU IFN
for 3 days.
No significant
reduction
in the
viability
of cells was noted after IFN treatment,
suggesting
that IFN have had no direct
cytotoxic
effect
on in-vitro
treated hairy
cells.
In a
correlative
study on these cases, Samuels et al.
[1986] have shown that the exposure to IFN also
caused
the induction of specific
proteins
in the
treated
HCs. The present study demonstrates
that
in 8 out of 11 HCL cases the exposure
to IFN
resulted
in specific
surface membrane changes,
in
19 to 36% of IFN-treated
HCs. The main changes
were the appearance of small bubbles in the cell
membrane and the smoothening of otherwise
very
active
surface areas which is often
accompanied
with the formation of a markedly villous
rud-like
process at the cell extremity.
An increase in HLA-A, B, c, and DR antigens
as
well
as beta
microglobulin,
after
IFN
2
treatment,
was observed on various human cells invitro and in-vivo [Lucero et al., 1982; Basham and
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Figs.
3a,b:
Control
hairy
cells
labeled
for Leu-MS
by colloidal
gold.
a. SE image of a control
cell.
b.
BE
image
(inverted)
of the same cell
(the
black dots represent
the marker).

Figs.
3c,d:
IFN-treated
hairy cells
labeled
for
Leu-MS by colloidal
gold . c.
SEI of
two cells
treated
with IFN in-vitro
(arrows point
to a budlike formation).
d.
BE image (inverted)
of same
cells.

Merigan,
1983; Rosa et al., 1983].
Burrone and
Milstein
(1982] have described a protein
of the
cell
surface of T-leukemic cells (Molt 4) and Blymphoblastoid
cells
(Raji or Daudi),
which is
stron;Jly
increased after treatment by alpha-IFN.
This protein becomes the major surface antigen
of
the IFN-treated
cells, but its function
is yet
unknown. On the other
hand,
human fibroblasts
treated
with IFN showed an increase in the level
of prostaglandin
E [Yaron et al.,
1977].
This
enhanced prostaglandin
synthesis was believed
to
be a feerl-back mechanism which protects
the cells
cgainst
excessive
membrane damage
by
IFN
[Fitzpatrick
am Strin;Jfella.v,
1980;
GurariRotman, 1982].
IFN was also shown to induce a reduction
in
the fluidity
of the cell
membrane, which is
closely
related
to
major
cytoskeletal
modifications.
Actin containin;J
microfilaments

were reported
to become more dense and form
meshworks under the membrane of IFN treaterl
HeLa
or L-929 cells [Tamm et al., 1982; Wang et al.,
1981]. IFN-induced changes in actin microfilaments
were also reported to impair cell surface receptor
movements and to inhibit capping of Concanavalin A
receptors
[Pfeffer et al., 1980a,b].
The unique IFN-induced morphological changes,
delineated
by SEMin the present
and previous
studies,
and the increased expression of class
II
HLA antigens demonstrated in the present
study,
most likely
reflect
alterations
in
membranal
and/or sub-membranal elements of the target
cell.
Membranal reorganization
probably plays
a major
role
in the response of the cells
to IFN, and
reflects
a distinct
change in the HCs that
might
initiate
their
disappearance
in HCL patients
treaterl with IFN in-vivo.
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Figs.
4a,b:
Control
hairy
cells
labeled
by colloidal
gold.
a.
SEI of a control
BEI (inverted)
of the same cell.

ljf' [ I 1:::
.

0002 20KU XS,500

-1~mWO17

Figs.
4c,d : IFN-treated
hairy
cells
labeled
for
HLA-DR by colloidal
gold.
c . SEI of a cell
treated
with
IFN in-vitro
(arrows
point
to
a bud-like
formation).
d. BEI (inverted)
of the same cell.

for HLA-DR
cell.
b.
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Discussion

et al.
Authors: We do agree that this is a most important
topic.
This whole issue is now under
intensive
study in our laboratory,
especially,
by the use of
sync hronized
cell samples. We do not agree with
the use of the word 'just'
in this context
since
our aim is to answer the question as to why IFN is
so effective
in some leukemias,
and is
not
effective
in others.
If a proper position
in the
cell
cycle
enables
IFN to react
effectively
through the changes that we described,
this
might
be 'just'
what we are trying to clarify.
M. Revel: Furthermore,
if changes were not seen in
1 out of 3 samples is there
any relation
to
response to treatment in-vivo?
Authors:
All 11 patients
in this
study
were
treated with IFN in-vivo.
Except in one case, they
all
reacted well to this treatment,
as indicated
by a decrease in the number of malignant cells
in
their
blood.
The exceptional
case also
did not
show morphological
changes in-vitro,
rut
on the
other hand, the cells from two other cases did not
display
merr.brane alterations
under the SEM, but
reacted
well to the drug in-vivo.
Thus,
further
studies
are necessary to correctly
relate
the
response in-vivo to that demonstrated
in-vitro
by
ultrastructure.

With Reviewers

M. Revel:
This work described
very
briefly
observations
made after incubating
1 sample of
spleen
cells
and 1 sample of peripheral
blood
cells fran hairy cell leukemia patients,
with 1000
U/ml
rIFN-alpha
for
24 hours.
Changes
in
morphology were observed by SEM on 20-30% of the
cells in these two cases, while no changes seem to
have been seen in a third case.
Authors:
The aim of this work was to review
for
SEM people the literature
on the ability
of IFN to
induce changes in target cells.
Beside that
goal,
it brought our results
regarding a total number of
7 cases, of which 3 were new ones. As was stressed
in the original
paper, the changes in morphology
were seen in 5 out of the 7 studied cases,
which
indicated
a unique phenomenon. In this
revised
manuscript we added 4 more cases, and reviewed the
results
from a total of 11 cases treated with IFN
in -v itro in our lab. These unique alterations
were
seen in 8 out of the 11 cases.

M. Revel:
Another unanswered question is whether
such "changes" are seen in other
lymphoid cells
than those of hairy cell leukemia?
Authors:
We are currently
studying various
types
of normal and leukemic leukocytes
treated
with IFN
in-vitro.
So far, none of these cell
types
did
show the same changes as did hairy
cells.
Daudi
(B-type
lymphoma cells)
do show some surface
membrane alterations,
mainly, with regard to the
distribution
of surface microvilli,
but
they do
not show extensive bubbling of the membrane like
the IFN-treated
hairy cells,
nor the same bud-like
formation.

M. Revel: Leaving aside the fact that the changes
illustrated
only by a couple of micrographs in the
unique
figure,
are difficult
to see for a nonexpert microscopist,
the question is whether these
20-30% of cells are all the hairy cells
in the
mononuclear
cell fraction
or whether only 20-30%
of the hairy cells are modified?
The number of
hairy
cells
(tartrate-resistant
phosphatase
positive,
or stained with specific
antibodies)
should be given for each sample examined.
Authors:
Having
in
mind
the
non-expert
microscopists,
we have
replaced
the
original
photographs
and
added others
that
clearly
demonstrate
the differences.
Regarding the numbers
of altered
cells,
we clearly
noted
that
the
changes were seen "in 22-31% of IFN-treated
HCs",
which refers to the absolute number of HCs, not to
the mononuclears.
Therefore,
the actualnumber
of
hairy cells in each case is not important,
but was
always more than 60% in the PB and more than 80%
in the spleen, as was noted in the Materials
and
Methods section.

Reviewer III: Other questions
that are unresolved
are,
for
example,
whether similar
changes
can
occur upon exposure of hairy
cell
leukemia
to
other
biologic
response
modifiers,
such
as
interleukin-2
or BCGF, factors
that have produced
biologic
response
in-vitro.
It is not
known
whether
an antibody
to interferon
alpha
will
abrogate
the observed results
(which is a final
test
to derive the conclusion
that these
changes
are related
to interferon).
Authors:
Hairy cells treated with either BCGF or
interleukin-2
did not show, in our laboratory,
same surface alterations
as did interferon-treated
hairy
cells.
On the other hand, when an adequate
neutralizing
concentration
of
anti-interferon
antiserum
was added to the interferon
treated
cultures,
it totally
inhibited
the induction
of
alterations
by interferon.
These facts prove
that
the initially
described
SEM surface
changes
are
specific
to interferon.

M. Revel:
If only a small
proportion
of hairy
cells
is
affected by IFN, is it
possible
that
these
changes
just reflect
the position
of the
cells
in the cell-cycle,
which could be affected
by IFN? This seems to me a most critical
point.

Reviewer IV: Did you observe
bud-like
only in IFN-treated
HCs, and did you
microvilli
of the treated cells of Fig.
shorter
than those of untreated
cells of
Authors: The answer to both questions
is
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formation
find
the
2b much
Fig. la?
- yes.

